Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023
31 Julho 2023 - 6:27PM
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage
biopharmaceutical company developing novel immuno-oncology
therapeutics for the treatment of cancer, today announced that
management will participate in a fireside chat at the BTIG Virtual
Biotechnology Conference 2023 on Monday, August 7, 2023, at 10:00
a.m. EDT (7:00 a.m. PDT).
A live webcast of the presentation will be available on the
Events and Presentations page of Bolt’s website
at www.boltbio.com. Archived replays will be available for 30
days following the event.
About Bolt Biotherapeutics, Inc. Bolt
Biotherapeutics is a clinical-stage biopharmaceutical company
developing novel immunotherapies for the treatment of cancer. Bolt
Biotherapeutics’ pipeline candidates are built on the Company’s
deep expertise in myeloid biology and cancer drug development. The
Company’s pipeline includes BDC-1001, a HER2-targeting Boltbody™
Immune-Stimulating Antibody Conjugate (ISAC); BDC-3042, a
myeloid-modulating antibody; and multiple Boltbody ISAC
collaboration programs. BDC-1001 is currently in Phase 2 clinical
development following the successful completion of a Phase 1
dose-escalation trial that demonstrated tolerability and early
clinical efficacy. BDC-3042, an agonist antibody targeting
Dectin-2, is expected to initiate a Phase 1 trial in the second
half of 2023. In preclinical development, BDC-3042 demonstrated the
ability to convert tumor-supportive macrophages to
tumor-destructive macrophages. Bolt Biotherapeutics is also
developing multiple Boltbody™ ISACs in strategic collaborations
with leading biopharmaceutical companies. For more information,
please visit https://www.boltbio.com/
Investor Relations and Media Contacts:Paige
KellyStern Investor Relations,
Inc.212-698-8699paige.kelly@sternir.com
David SchullRusso Partners,
LLC858-717-2310david.schull@russopartnersllc.com
Bolt Biotherapeutics (NASDAQ:BOLT)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Bolt Biotherapeutics (NASDAQ:BOLT)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024